For Health Care Professionals Outside the US

It’s Time to Look Beyond Immunosuppression
for Sustained Response

NEW INDICATION

  • Now approved in ITP for use 6 months after diagnosis1

COVID-19 has become a major public health challenge around the world. We know that you, and your patients, are looking for answers. The American Society of Hematology (ASH) has put together a series of FREQUENTLY ASKED QUESTIONS to provide certain relevant information surrounding this novel virus and the hematologic conditions you treat.

See what ASH has to say about COVID-19 and ITP
See what ASH has to say about COVID-19 and Aplastic Anemia
Patients can achieve sustained response with REVOLADE
In immune thrombocytopenic purpura (ITP)
Patients can achieve SUSTAINED RESPONSE with REVOLADE2
Review the ITP data
Patients’ response continued after discontinuation of treatment with REVOLADE+immunosuppressive therapy
In relapsed/refractory severe aplastic anaemia (SAA)
REVOLADE monotherapy enables patients to achieve a MULTILINEAGE RESPONSE1
Review the SAA data

REVOLADE is the TPO-RA proven in the most disease states1

REVOLADE is indicated for the treatment of:

  • Patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (eg, corticosteroids, immunoglobulins)
  • Adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy
  • Adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation
TPO-RA, thrombopoietin receptor agonist.

References:

1. REVOLADE Summary of Product Characteristics. February 2019. 2. Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(3):2527-2536.

© 2019 Novartis | Use of this website is subject to our Terms of Use
Disclaimer: This is an international website for REVOLADE® (eltrombopag) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents links at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.